Hydrocortisone Butyrate

證據等級: L5

預測適應症: 0 個

Hydrocortisone Butyrate: Evaluation Report — No Repurposing Predictions Available

One-Sentence Summary

Hydrocortisone butyrate (DB14540) is a corticosteroid compound currently not registered with SAHPRA in South Africa. The TxGNN model has not generated any repurposing predictions for this drug at this time — the evidence pack contains no predicted indications, no clinical trial evidence, and no supporting literature. This report documents the outstanding data gaps and recommends a Hold decision pending data completion.

Quick Overview

Item	Content
Original Indication	Not available in current evidence pack
Predicted New Indication	None — no TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions or supporting evidence available
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why No Prediction Is Available

The current evidence pack for hydrocortisone butyrate (DB14540) is incomplete in two critical areas that prevent the TxGNN pipeline from generating repurposing candidates:

1. No original indication data on record. The SAHPRA regulatory data returns zero licences and no approved indication text. Without a documented therapeutic starting point, the model lacks the anchoring context required to rank and surface plausible new indications.

2. Mechanism of action (MOA) unavailable. A DrugBank query was successfully executed (query log entry 1, 2026-03-26), returning one result record; however, no MOA data was captured in the output. MOA is classified as a High-severity data gap (DG002) because mechanistic rationale is central to assessing the biological plausibility of any repurposing prediction.

Note for reviewers: Hydrocortisone butyrate is broadly recognised in pharmacological literature as a medium-potency topical glucocorticoid used for inflammatory dermatoses; however, this background knowledge is not formally structured within the current evidence pack and cannot substitute for the required data fields in the TxGNN evaluation workflow.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Hydrocortisone butyrate is not currently registered with SAHPRA and holds no South African product licences. No Essential Medicines List (EML) inclusion applies.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing predictions have been generated, and all critical evaluation fields — original indication, mechanism of action, and safety information — are absent from the current evidence pack. There is no evidentiary basis on which to assess or recommend a repurposing pathway at this stage.

To proceed, the following is needed:

[Blocking — DG001] Retrieve SAHPRA-approved Professional Information (PI) to populate warnings and contraindications; without this, the safety screening step (S1) cannot be initiated
[High — DG002] Query the DrugBank API directly for DB14540 to extract MOA, drug categories, and toxicity data; confirm whether the returned record contains populated pharmacology fields
Verify TxGNN node coverage: Confirm that hydrocortisone butyrate (DB14540) is present as a valid drug node in the TxGNN knowledge graph (data/node.csv); if absent, the prediction pipeline will silently return zero results
Document original approved indications: Register at least one structured indication (e.g., topical inflammatory skin conditions such as eczema or psoriasis) to enable the model to compute disease-similarity scores
Re-run the full prediction pipeline once the above gaps are resolved, then regenerate this evidence pack at version ≥ v5
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.